Investors

Investor overview

Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections​. UK-based and AIM listed, we were founded in 2003 as a spin-out from the University of Southampton.

With over two million people hospitalised each year in the US, respiratory viruses pose a significant threat to global public health and continue to be a major cause of hospitalisations. SNG001 is a host-directed, broad-spectrum antiviral that directly targets the site of infection​ - the lungs. Its mode of action does not depend on a particular virus or variant.

Synairgen has completed a comprehensive review of data from previous trials of SNG001, epidemiological data, commercial factors and unmet clinical need, concluding that mechanically ventilated patients in intensive care are the most appropriate group to target in the next clinical trial. With only one antiviral drug approved for adults in the US (remdesivir for COVID-19) for use in mechanically ventilated patients, these difficult and expensive to treat patients are underserved with currently available antiviral treatments and mortality remains high in the range of 25-45 per cent. Subject to regulatory approvals, Synairgen plans to initiate a Phase 2 clinical trial (SG021) in mechanically ventilated patients with confirmed respiratory viral infections during the coming 2024/2025 virus season.

With input from clinical advisers, a review of data across our clinical development programmes further supports our approach to investigate SNG001 as a broad-spectrum antiviral for a range of respiratory viral infections.